Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues

US10265372B2 · kind B2 · utility

Assignee

• The Regents of the University of California · US

Inventors

• Irina M. Conboy · El Sobrante, US
• David V. Schaffer · Danville, US
• Hanadie Yousef · San Mateo, US
• Michael J. Conboy · El Sobrante, US
• Wendy Cousin · Belmont, US
• Christian Elabd · Belmont, US

Key dates

• Filing date: Aug 12, 2015
• Grant date: Apr 23, 2019
• Expiry date: Aug 12, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2501/999
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods, pharmaceutical compositions, and kits are provided for treating a subject with an effective amount of an oxytocin receptor (OXTR) agonist and an effective amount of an ALK5 antagonist. In certain aspects, the OXTR agonist may be oxytocin or an oxytocin analog (e.g., a small molecule). The ALK 5 antagonist may be a small molecule, such as 2-(3-(6-Methyl-pyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine, LY2157299, A 83-01, D 4476, GW 788388, LY 364947, Rep Sox, SB 431542, SB 505124, SB 525334, or SD 208. In certain aspects, the amounts of the OXTR agonist and ALK5 antagonist may be sufficient to induce muscle regeneration and/or neural cell regeneration in the subject.